Scientific Advisory BoardIn June 2007 Arana established a scientific advisory board. External board members are:Sir Gregory Winter PhD, CBE, FRS, FMedSci, HonFRCP, Sir Gregory Winter is Deputy Director of the Medical Research Council’s Laboratory of Molecular Biology (LMB). He is a pioneer of protein engineering. In particular he developed technologies for making humanised antibodies and also for making human antibodies in bacteria (by use of antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market were developed using methods devised by him. He was a founder and director of Cambridge Antibody Technology, a founder and director of Domantis and served as a director of Peptech between 2001-2003. Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to Molecular Biology. Professor Mark Hogarth PhD Professor Hogarth is regarded as a world leader in the study of autoimmune inflammation, with more than 100 scientific papers published. During his doctoral training Professor Hogarth was one of the first investigators to successfully produce monoclonal antibodies in Australia. He is Head of the Centre for Immunology at the Burnet Institute. Professor Hogarth is a Senior Principal Research Fellow of the NHMRC. His many achievements have been recognised by the Australian Academy of Science who awarded him the Gottschalk Medal for excellence. Professor Hogarth, who has published widely in peer reviewed journals, holds editorial positions on national and international scientific journals and has served on national grant committees. Professor Sir Ravinder Maini FRCP, FMedSci, Sir Ravinder has a long and distinguished medical career and his research interests encompass immunotherapy, autoantibody production, measurement and pathogenesis. He is currently Emeritus Professor of Rheumatology at Imperial College, University of London, UK, Trustee of the Kennedy Institute of Rheumatology, London, UK and Emeritus Honorary Consultant Physician at Charing Cross Hospital, Hammersmith Hospitals Trust, London, UK. He is a Fellow of the Academy of Medical Sciences and the Royal Society, was knighted in 2003 and is a co-recipient of the Crafoord Prize from the Swedish Academy of Sciences in 2000 and the Albert Lasker Clinical Medical Research Award (U.S.) in 2003. He is a member of a number of prestigious international societies, committees and clubs, co-edits Arthritis Research and Therapy and has published over 400 articles in refereed journals and invited reviews. Till Medinger MA, DPhil, Oxford Dr Medinger brings a wealth of international public company experience to the scientific advisory board. His distinguished international career has spanned R&D, licensing and acquisition, strategic planning and marketing management in the pharma-ceutical industry including the launch of several products that achieved ‘blockbuster’ global success. He served as Senior Vice President for Corporate Strategy at AstraZeneca Plc and prior to that had a long and distinguished career with Zeneca and ICI Pharmaceuticals, directing business and marketing operations internationally. He was President of the Association of the British Pharmaceutical Industry from 1994 to 1996. His service on boards includes both European and the International Pharmaceutical Industry Federations, as a Non-executive Director of Peptech Ltd, an alternate Director of Domantis Ltd, Chairman of PhotoBiotics Ltd and Director of Datapharm Communications Ltd, Polytherics Ltd and ML Laboratories PLC. He has also acted as a corporate consultant to a number of emerging high-tech companies within the U.S. and the UK. |
 |